Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23825507 | 1.00 | SORT1 (1.00) | SORT1MEN1KMT2AALDH1A1STAT3 | |
| SCHEMBL23825504 | 0.85 | SORT1 (0.74) | SORT1ALDH1A1 | |
| SCHEMBL29980628 | 0.85 | SORT1 (0.74) | SORT1ALDH1A1 | |
| SCHEMBL3356211 | 0.84 | MEN1 (1.00) | SORT1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL823197 | 0.82 | MEN1 (0.75) | SORT1MEN1KMT2AALDH1A1STAT3 | |
| SCHEMBL16351642 | 0.82 | MEN1 (0.75) | SORT1MEN1KMT2AALDH1A1STAT3 | |
| SCHEMBL2783819 | 0.82 | MEN1 (0.75) | SORT1MEN1KMT2AALDH1A1STAT3 | |
| SCHEMBL26808975 | 0.80 | AKR1C2 (0.67) | SORT1MEN1KMT2AALDH1A1STAT3 | |
| SCHEMBL22681802 | 0.79 | SORT1 (0.65) | SORT1MEN1KMT2AALDH1A1LRRK2 | |
| SCHEMBL13964393 | 0.79 | SORT1 (0.65) | SORT1MEN1KMT2AALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115297856-A | Sortilin antagonists for the treatment of diabetic retinopathy | 舒感有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| CN-115297856-A | Sortilin antagonists for the treatment of diabetic retinopathy | 舒感有限公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | SORT1, SCARB1, NRP1 | SORT1 1/4885MEN1 3577/4885KMT2A 4786/4885 |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | SORT1, NTSR2, SLC17A5 | SORT1 1/4885MEN1 1693/4885KMT2A 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.